Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 09.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | n Form 8-K is incorporated by reference into this Item 5.02. In accordance with the terms of the Merger Agreement, at th |
| 31.03.2025 | Item 4.02 — Bilanzkorrekturen | EXTREM | SEC | ttee have discussed the matters described in this Item 4.02 with its independent registered public accounting firm, Erns |
Stammdaten
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Unternehmen & Branche
| Name | Adverum Biotechnologies, Inc. |
|---|---|
| Ticker | ADVM |
| CIK | 0001501756 |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 96,3 Mio. USD |
| Beta | 0,87 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-09-30 | 10-Q | 0 | -47,652,000 | -2.03 | 72,401,000 | -55,653,000 |
| 2025-06-30 | 10-Q | -49,191,000 | -2.34 | 96,179,000 | -20,219,000 | |
| 2025-03-31 | 10-Q | -47,019,000 | -2.25 | 137,654,000 | 26,422,000 | |
| 2024-12-31 | 10-K | 1,000,000 | -130,927,000 | -6.62 | 179,841,000 | 70,714,000 |
| 2024-09-30 | 10-Q | 1,000,000 | -32,351,000 | -1.55 | 234,375,000 | 108,270,000 |
| 2024-09-30 | 10-K | 1,000,000 | -32,351,000 | -1.55 | 210,244,000 | 108,270,000 |
| 2024-06-30 | 10-Q | 0 | -30,498,000 | -1.46 | 253,803,000 | 137,400,000 |
| 2024-06-30 | 10-K | -30,498,000 | -1.46 | 229,599,000 | 137,400,000 | |
| 2024-03-31 | 10-Q | 0 | -27,147,000 | -1.65 | 267,828,000 | 163,681,000 |
| 2024-03-31 | 10-K | -27,147,000 | -1.65 | 250,546,000 | 163,681,000 | |
| 2023-12-31 | 10-K | 3,600,000 | -122,116,000 | -12.11 | 155,768,000 | 67,222,000 |
| 2023-09-30 | 10-Q | 0 | -32,885,000 | -3.26 | 196,770,000 | 102,714,000 |
| 2023-09-30 | 10-K | 0 | -33,415,000 | -3.31 | 179,612,000 | 87,257,000 |
| 2023-06-30 | 10-Q | 0 | -31,510,000 | -3.13 | 241,429,000 | 131,155,000 |
| 2023-06-30 | 10-K | 0 | -32,525,000 | -3.23 | 224,375,000 | 116,228,000 |
| 2023-03-31 | 10-K | 3,600,000 | -31,672,000 | -3.16 | 252,672,000 | 143,845,000 |
| 2023-03-31 | 10-Q | 3,600,000 | -29,056,000 | -2.90 | 275,577,000 | 157,757,000 |
| 2022-12-31 | 10-K | 0 | -154,536,000 | -1.56 | 308,372,000 | 170,222,000 |
| 2022-09-30 | 10-Q | 0 | -40,131,000 | -0.40 | 332,362,000 | 208,337,000 |
| 2022-06-30 | 10-Q | 0 | -43,761,000 | -0.44 | 374,955,000 | 244,122,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-08 | Fischer Laurent | Director, Officer, CEO, PRESIDENT AND DIRECTOR | Open Market Purchase | 117,614 | 4.31 | 506,916.34 | +93,9% | |
| 2025-12-05 | Soparkar Peter | Officer, CHIEF OPERATING OFFICER | Open Market Purchase | 50,000 | 4.22 | 211,000.00 | +39,1% | |
| 2025-12-05 | Fischer Laurent | Director, Officer, CEO, PRESIDENT AND DIRECTOR | Open Market Purchase | 11,085 | 4.24 | 47,000.40 | +8,7% | |
| 2025-12-04 | Leonard Braden Michael | 10% Owner | Open Market Sale | -524,560 | 4.19 | -2,200,371.83 | -407,5% | |
| 2025-12-03 | Leonard Braden Michael | 10% Owner | Open Market Sale | -222,925 | 4.17 | -929,597.25 | -172,2% | |
| 2025-12-02 | Leonard Braden Michael | 10% Owner | Open Market Sale | -51,961 | 4.20 | -218,236.20 | -40,4% | |
| 2025-12-01 | Leonard Braden Michael | 10% Owner | Open Market Sale | -300,000 | 4.20 | -1,260,000.00 | -233,4% | |
| 2025-05-15 | Fischer Laurent | Director, Officer, CEO, PRESIDENT AND DIRECTOR | Open Market Sale | -9,126 | 2.00 | -18,252.00 | -3,4% | |
| 2025-05-15 | Soparkar Peter | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -2,960 | 2.00 | -5,920.00 | -1,1% | |
| 2025-05-15 | Seyedkazemi Setareh | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -924 | 2.00 | -1,848.00 | -0,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.